Trials / Active Not Recruiting
Active Not RecruitingNCT06485089
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers in Women With Obesity and Other Risk Factors for Breast Cancer
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- University of Kansas Medical Center · Academic / Other
- Sex
- Female
- Age
- 40 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.
Detailed description
Women who are scheduled to take tirzepatide for weight loss will be assessed before and after taking drug for change in risk biomarkers. These include mammography, DXA scan, blood draw, and random periareolar fine needle aspiration (RPFNA) for acquisition of benign breast tissue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tirzepatide | Women taking tirzepatide as part of standard care in the Weight Managment Clinic |
Timeline
- Start date
- 2024-09-14
- Primary completion
- 2026-02-01
- Completion
- 2026-04-01
- First posted
- 2024-07-03
- Last updated
- 2025-10-29
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06485089. Inclusion in this directory is not an endorsement.